Burak Gümüşçü

5.1k total citations
28 papers, 778 citations indexed

About

Burak Gümüşçü is a scholar working on Oncology, Otorhinolaryngology and Epidemiology. According to data from OpenAlex, Burak Gümüşçü has authored 28 papers receiving a total of 778 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 9 papers in Otorhinolaryngology and 8 papers in Epidemiology. Recurrent topics in Burak Gümüşçü's work include Cancer Immunotherapy and Biomarkers (17 papers), Head and Neck Cancer Studies (9 papers) and Nonmelanoma Skin Cancer Studies (7 papers). Burak Gümüşçü is often cited by papers focused on Cancer Immunotherapy and Biomarkers (17 papers), Head and Neck Cancer Studies (9 papers) and Nonmelanoma Skin Cancer Studies (7 papers). Burak Gümüşçü collaborates with scholars based in United States, Spain and Australia. Burak Gümüşçü's co-authors include Thomas A. Reh, Jennie Close, Brett Hughes, Byron H. Hartman, Branden R. Nelson, Ramona F. Swaby, Kevin J. Harrington, Florent Grange, Jean‐Jacques Grob and Jacob Schachter and has published in prestigious journals such as Journal of Clinical Oncology, Development and Cancer Research.

In The Last Decade

Burak Gümüşçü

27 papers receiving 757 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Burak Gümüşçü United States	11	373	294	199	107	96	28	778
Steven Margossian United States	13	161 0.4×	664 2.3×	62 0.3×	60 0.6×	20 0.2×	32	922
Kunzang Chosdol India	18	191 0.5×	432 1.5×	98 0.5×	80 0.7×	5 0.1×	58	875
Rebekka Duhen United States	11	737 2.0×	214 0.7×	70 0.4×	1.1k 10.4×	15 0.2×	21	1.4k
John Hall United Kingdom	10	174 0.5×	1.7k 5.8×	35 0.2×	96 0.9×	87 0.9×	11	2.0k
K Braham France	7	282 0.8×	178 0.6×	59 0.3×	146 1.4×	16 0.2×	8	590
Vincenza Morello Italy	13	183 0.5×	152 0.5×	21 0.1×	12 0.1×	22 0.2×	24	415
Jeffrey N. Myers United States	10	208 0.6×	217 0.7×	20 0.1×	29 0.3×	53 0.6×	12	479
Andrea M. Sheehan United States	11	581 1.6×	251 0.9×	98 0.5×	376 3.5×	23 0.2×	23	919
Korinna Pilz Germany	12	327 0.9×	220 0.7×	93 0.5×	87 0.8×	5 0.1×	17	706
Mary Paniagua United States	11	150 0.4×	86 0.3×	39 0.2×	278 2.6×	60 0.6×	15	591

Countries citing papers authored by Burak Gümüşçü

Since Specialization

Citations

This map shows the geographic impact of Burak Gümüşçü's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Burak Gümüşçü with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Burak Gümüşçü more than expected).

Fields of papers citing papers by Burak Gümüşçü

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Burak Gümüşçü. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Burak Gümüşçü. The network helps show where Burak Gümüşçü may publish in the future.

Co-authorship network of co-authors of Burak Gümüşçü

This figure shows the co-authorship network connecting the top 25 collaborators of Burak Gümüşçü. A scholar is included among the top collaborators of Burak Gümüşçü based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Burak Gümüşçü. Burak Gümüşçü is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tahara, Makoto, Richard Greil, Danny Rischin, et al.. (2025). Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up from the randomized phase III KEYNOTE-048 study. European Journal of Cancer. 221. 115395–115395. 6 indexed citations

Tao, Yungan, Lillian L. Siu, Lisa Licitra, et al.. (2025). Long-term results of the randomized, phase 3 KEYNOTE-412 trial of pembrolizumab (pembro) or placebo (pbo) plus concurrent chemoradiotherapy (CRT) for unresected, locally advanced head and neck squamous cell carcinoma (LA HNSCC).. Journal of Clinical Oncology. 43(16_suppl). 6013–6013. 2 indexed citations

Muñoz‐Couselo, Eva, Brett Hughes, Laurent Mortier, et al.. (2024). Pembrolizumab (pembro) for locally advanced (LA) or recurrent/metastatic (R/M) cutaneous squamous cell carcinoma (cSCC): Long-term results of the phase 2 KEYNOTE-629 study.. Journal of Clinical Oncology. 42(16_suppl). 9554–9554. 3 indexed citations

Klochikhin, A L, Robert I. Haddad, Amichay Meirovitz, et al.. (2023). KEYNOTE-689: A Phase 3 Study of Neoadjuvant and Adjuvant Pembrolizumab Plus Standard of Care (SOC) in Resectable, Locally Advanced (LA) Head and Neck Squamous Cell Carcinoma (HNSCC). European Journal of Surgical Oncology. 49(1). e9–e9. 3 indexed citations

Bratland, Åse, Eva Muñoz‐Couselo, Laurent Mortier, et al.. (2023). Health-Related Quality of Life with Pembrolizumab in Patients with Locally Advanced or Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: KEYNOTE-629. Dermatology and Therapy. 13(12). 3165–3180. 1 indexed citations

Klochikhin, A L, Robert I. Haddad, Amichay Meirovitz, et al.. (2023). Abstract PO-002: Pembrolizumab as neoadjuvant and adjuvant therapy in combination with standard of care in resectable, locally advanced head and neck squamous cell carcinoma: Phase 3 KEYNOTE-689. Clinical Cancer Research. 29(18_Supplement). PO–2. 1 indexed citations

Polewski, Monika D., Malinka Jansson, Kenneth Emancipator, et al.. (2021). Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Head and Neck Squamous Cell Carcinoma. 5(1). 9–17. 2 indexed citations

Hughes, Brett, René González Mendoza, Nicole Basset‐Séguin, et al.. (2021). Health-Related Quality of Life of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma Treated with Pembrolizumab in KEYNOTE-629. Dermatology and Therapy. 11(5). 1777–1790. 9 indexed citations

Harrington, Kevin J., Anthony Kong, Nicolas Mach, et al.. (2021). Final analysis of a phase 1b, randomized, multicenter study of talimogene laherparepvec (T-VEC) plus pembrolizumab (pembro) combination for the treatment (Tx) of recurrent/metastatic squamous cell carcinoma of the head and neck (R/M HNSCC): MASTERKEY-232.. Journal of Clinical Oncology. 39(15_suppl). 6036–6036. 4 indexed citations

10.

Harrington, Kevin J., Anthony Kong, Nicolas Mach, et al.. (2020). Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study. Clinical Cancer Research. 26(19). 5153–5161. 83 indexed citations

11.

Grob, Jean‐Jacques, René González, Nicole Basset‐Séguin, et al.. (2020). Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629). Journal of Clinical Oncology. 38(25). 2916–2925. 188 indexed citations

12.

Grob, Jean‐Jacques, René González, Nicole Basset‐Séguin, et al.. (2019). KEYNOTE-629: Phase 2 study of pembrolizumab for recurrent/metastatic or locally advanced unresectable cutaneous squamous cell carcinoma (cSCC).. Journal of Clinical Oncology. 37(15_suppl). TPS9598–TPS9598. 5 indexed citations

13.

Rischin, Danny, Kevin J. Harrington, Richard Greil, et al.. (2019). Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).. Journal of Clinical Oncology. 37(15_suppl). 6000–6000. 101 indexed citations

14.

Gümüşçü, Burak, et al.. (2016). Well-differentiated neuroendocrine tumor of the stomach. Medicine. 95(29). e4260–e4260. 2 indexed citations

15.

Wynn, Tung & Burak Gümüşçü. (2016). Potential role of a new PEGylated recombinant factor VIII for hemophilia A. Journal of Blood Medicine. 7. 121–121. 21 indexed citations

16.

Gümüşçü, Burak, et al.. (2013). Successful Unrelated Cord Blood Transplantation For Homozygous α-Thalassemia. Journal of Pediatric Hematology/Oncology. 35(7). 570–572. 8 indexed citations

17.

Nelson, Branden R., Burak Gümüşçü, Byron H. Hartman, & Thomas A. Reh. (2006). Notch Activity Is Downregulated Just prior to Retinal Ganglion Cell Differentiation. Developmental Neuroscience. 28(1-2). 128–141. 71 indexed citations

18.

Close, Jennie, et al.. (2006). Epidermal growth factor receptor expression regulates proliferation in the postnatal rat retina. Glia. 54(2). 94–104. 93 indexed citations

19.

Close, Jennie, Burak Gümüşçü, & Thomas A. Reh. (2005). Retinal neurons regulate proliferation of postnatal progenitors and Muller glia in the rat retina via TGFβ signaling. Development. 132(13). 3015–3026. 96 indexed citations

20.

Gümüşçü, Burak, et al.. (2002). Clinical implications of concomitant variations of the testicular, suprarenal and renal veins: A case report. Annals of Anatomy - Anatomischer Anzeiger. 184(1). 35–39. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact